Category: News

To best understand the medicinal cannabis opportunity currently knocking on our door, says one of Australia’s leading biotech investors, we must cast our minds back to a landmark event that occurred 89 years ago.

Tracking your wealth can be an addictive pursuit, especially when the market gods are smiling on you. And, well, it turns out that tracking the wealth of billionaires in real time can be quite captivating too.

Gold companies have had a long relationship with Australian exchanges, dating back to the mid 1800s when Ballarat had its own exchange to cater to the booming gold rush.

Every second week we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In June, Capital H Management’s Harley Grosser selected Allegiance Coal as one of his favourite stocks, noting its projections could make it…

Investors have welcomed the TGA’s decision to down-schedule low-dose cannabidiol (CBD) products to Schedule 3 (S3) as this will allow pharmacies to offer the products over the counter and is expected to help centralise a scattered market – with the potential new market estimated to dwarf the current highly regulated $250 million market, at over $3 billion.

Another 25 basis point rate hike has brought the cash rate up to 2.85% and drawn defence from the RBA, with governor Philip Lowe highlighting the greater risks associated with the slower rate lifting path they could’ve taken.

As an activated carbon product producer, Carbonxt Group Ltd (ASX: CG1) considers it has an important role to play in the decarbonisation of Earth. The company develops and markets products that are able to capture the contaminants from industrial processes that would normally emit substantial amounts of harmful pollutants.

A ‘concerning’ number of Australian adults are financially illiterate, prompting the ASX to join more than 80 securities exchanges and clearing houses worldwide to bring awareness to the goal of raising financial literacy in communities.

The local bourse has had a decent week, with the ASX 200 adding 0.28% since last Tuesday. The US enjoyed a bigger lift, with the S&P 500 surging 3.74% in the same period of time – largely spurred on by its economy likely having smaller rate hikes going forward.

An ASX-listed oncology company’s first-in-class cancer drug has shown encouraging clinical activity in a difficult-to-treat patient population, as per newly released results from an ongoing study.

The ASX has recognised FY22 as a record year for capital raises – with $159.4 billion invested overall – and some Aussie businesses still appear to be riding the wave of positive investor sentiment.

Every second week, we invite a leading fund manager to present at The Insider: Meet the Fund Manager. In May, Katana Asset Management’s Romano Sala Tenna selected Kina Securities as one of his favourite stocks, noting its sustained competitive advantage…